Reduce development risk from concept through production.
The commercial argument for outside expertise here is narrow and specific: it avoids having to hire a number of PhD scientists and engineers to obtain creativity and problem-solving capability that a programme needs intensively for a period and then does not need at that level again.
The through-line of this practice is the relationship between formulation, structure, processing, morphology, properties and performance — across all classes of materials. That chain is where development programmes usually stall, because a change made at one end produces an unexplained result at the other.
Bench-to-pilot-to-production transitions fail for reasons that are predictable in advance: shear and thermal history differ, residence-time distributions differ, mixing quality differs, and a formulation tuned to a laboratory process can be intolerant of the production one. Identifying which of those a given formulation is sensitive to, before the capital is committed, is usually the highest-value point in the programme.
Where an off-the-shelf material will not reach the target, the route may be a blend, a hybrid, a nanocomposite, a modified surface or a reformulated system. Direct research experience across organic–inorganic hybrids, nanocomposites, biomaterials, magnetic materials and glass–polymer systems informs whether a proposed route is promising or a known dead end.
Where development produces something protectable, support is available for patent applications and for positioning the work so that it can be protected — drawing on direct experience as a named inventor and on prior-art and patentability work. See Expert Witness & Litigation Support.
The highest-value point is early — before tooling investment commits you to a material or geometry. Independent review at the formulation or prototype stage catches problems that are cheap to fix there and expensive to fix in production.
Yes. Specialty polymers, blends, composites and nanocomposites have been a research and industrial focus for four decades. Formulation work, scale-up from lab to pilot to production, and supplier qualification are all within scope.
Yes. The typical arrangement is a defined scope of independent review rather than a displacement of your team. Where your team already has testing arrangements or supplier relationships, that work is specified, reviewed and interpreted rather than duplicated.
A short conversation is usually enough to tell whether independent technical review is worth it — and if it is not, you will be told so.
Describe what is happening, what it is costing and what decision is waiting on it. You will get a direct assessment of whether and how this can be investigated.
Discuss Your ChallengeSend the parties and the technical subject matter only — no case details, no documents. Conflicts are cleared before any substantive discussion takes place.
Request a Conflict Check